Search Results 2101-2110 of 19694 for Hemoglobin

1. A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with GRPR+, ER+, HER2- metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibito - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL;; International Normalized Ratio (INR) ≤ 1.5;; Creatinine Clearance ≥ 60 mL/min using the Chronic Kidney Disease Epidemiology ...

2. Ulixertinib in People With Histiocytic Neoplasms - Mayo Clinic

   Adequate bone marrow function (hemoglobin ≥9.0 g/dL, platelets ≥100 x 10^9 cells/L, absolute neutrophil count ≥1.5 x 10^9 cells/L). Patients with ...

3. Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05) - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (red blood cell/plasma transfusion is not allowed within 1 week prior to screening assessment);; Absolute neutrophil count ≥1500/mm3 ...

4. A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count (ANC) ≥ 1.5 × 10^9 /L;; Creatinine clearance ≥ 30 mL/min as calculated using the Cockcroft-Gault equation ...

5. Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery - Mayo Clinic

   Hemoglobin (Hgb) ≥ 9 g/dL (within less than or equal to 14 days prior to randomization). Leukocytes ≥ 3,000/mm^3 (within less than or equal to 14 days ...

6. A Study to Assess the Effectiveness and Safety of Durvalumab Alone or Combined with Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment - Mayo Clinic

   Hemoglobin ≥ 9 g/dL;; Absolute neutrophil count ≥ 1000/µL;; Platelet count ≥ 65000/µL;; Total bilirubin (TBL) ≤ 2.0 × upper limit of normal (ULN); ...

7. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

   * subjects in the venetoclax + JCAR017 combination must have hemoglobin \>=9 g/dL, absolute neutrophil count \>=500mm3 and platelets\>= 75,000/mm3, unless ...

8. Hematology - Clinical trials

   In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

9. A Study to Test Combination Treatments in Patients With Advanced Gastric Cancer - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL (transfusion to achieve this level is not permitted within 2 weeks of the first study treatment administration);; Alanine ...

10. Neurosurgery - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...